Y-Prime_Logo_rgb_color.png
YPrime Recognized as Trailblazer in Patient Engagement by Everest Group
24 sept. 2024 08h42 HE | Y-Prime, LLC
YPrime has been recognized as a Trailblazer in patient engagement by Everest Group for its innovative solutions that enhance clinical trial participation.
NoomWSJ924adv10
Noom Calls for Affordable Choices and Fair Pricing of Weight-Loss Medications Ahead of Tuesday’s Senate Testimony
24 sept. 2024 07h02 HE | Noom Inc
Noom issued a call for public support of a new petition demanding affordable choices and fair pricing for GLP-1 weight-loss medications.
Summit C3 wrap up
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
18 sept. 2024 06h00 HE | King Faisal Specialist Hospital & Research Centre
KFSHRC Celebrates Landmark Contributions at 2024 NYC C3 Summit Davos of Healthcare
#4_Dr.Baz
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
17 sept. 2024 08h48 HE | King Faisal Specialist Hospital & Research Centre
KFSHRC at the forefront of precision medicine and genomic therapies in Saudi Arabia and the region
#3_Dr. Cupler
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
17 sept. 2024 04h29 HE | King Faisal Specialist Hospital & Research Centre
KFSHRC Drives Saudi Arabia’s Rise as Global Biotech Powerhouse
#1 PLR-
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
16 sept. 2024 14h06 HE | King Faisal Specialist Hospital & Research Centre
KFSHRC Deputy CEO Receives Global Innovative Healthcare & Impact Transformation Award at New York Summit
23andMe_Logo_grey.png
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
15 sept. 2024 03h00 HE | 23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe_Logo_grey.png
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
15 sept. 2024 03h00 HE | 23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...
23andMe_Logo_grey.png
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
12 sept. 2024 16h05 HE | 23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Noom GLP-1
Noom Introduces Industry-First $149 Compounded GLP-1 with a Taper-Off Guarantee, Offering a Sustainable Approach to Long-Term Weight Loss
12 sept. 2024 08h03 HE | Noom Inc
Noom will offer compounded GLP-1 injections paired with Noom’s powerful GLP-1 companion program, providing a sustainable pathway off the medications.